Renal mass biopsies more cost-effective, prevent unnecessary procedures

Article

The use of renal mass biopsy to guide treatment decisions for small renal tumors is cost-effective relative to direct surgery, and can spare many patients unnecessary surgical procedures, according to Massachusetts General Hospital researchers.

The use of renal mass biopsy to guide treatment decisions for small renal tumors is cost-effective relative to direct surgery, and can spare many patients unnecessary surgical procedures, according to Massachusetts General Hospital researchers.

Most small renal masses are detected incidentally in imaging and their current treatment is direct surgery, said lead researcher Dr. Pari Pandharipande, a radiologist in the abdominal imaging and interventional radiology department at MGH. Many small renal masses, however, are benign-or indolent if they are malignant-and so less invasive management strategies should be considered, she said during a presentation at the RSNA meeting.

After constructing a decision-analytic Markov model, the researchers determined surgery was about $3500 more expensive than biopsy and resulted in a comparable minimally lower life expectancy. Biopsy therefore dominated surgery from a cost-effectiveness perspective.

The researchers assumed a biopsy sensitivity of 90% and specificity of 100%. The researchers also assumed a postsurgery mortality rate of 1.6%. Among imaging-detected masses, 77% were assumed to reflect renal cell carcinoma.

Biopsy did not dominate surgery under some conditions, for example, when sensitivity was lower than 78%, when surgical mortality was less than 1%, and when prevalence of renal cancer was greater than 87%.

The researchers used a competing-choices cost-effectiveness analysis to compare biopsy with surgery. If one strategy had a lower life expectancy and a higher cost than another, it was considered dominated. If not, an incremental cost-effectiveness ratio was computed and strategy preference was assessed based on an assumed $75,000 per quality adjusted life year societal willingness-to-pay threshold. The long-term outcomes of life expectancy and lifetime costs after biopsy and surgery were estimated by using a decision-analytic Markov model. The cohort in the base-case analysis was 65-year-old men with incidental renal masses.

All patients started with small incidental renal masses and underwent either surgery or biopsy. Patients receiving biopsy could have a true or false positive or negative result. Patients with negative biopsy results underwent CT surveillance for up to five years. Patients with positive and nondiagnostic biopsy specimens underwent direct surgery.   

This story has been updated to better reflect Dr. Pandharipande's research.
 

Recent Videos
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
Related Content
© 2025 MJH Life Sciences

All rights reserved.